Use of .alpha.-1C specific compounds to treat benign prostatic hyperplasia

US5578611A · kind A · utility

Assignee

• Synaptic Pharmaceutical Corporation · US

Inventors

• Charles Gluchowski · Mission Viejo, US
• Carlos Forray · Paramus, US
• George Chiu · Bound Brook, US
• Theresa Branchek · Teaneck, US
• John Wetzel · Elmwood Park, US
• Paul R. Hartig · Mahwah, US

Key dates

• Filing date: Apr 13, 1994
• Grant date: Nov 26, 1996
• Expiry date: Apr 13, 2014

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2602/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The subject invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, a human histamine H.sub.1 receptor and .alpha..sub.2 adrenergic receptor. The subject invention also provides a method of inhibiting contraction of prostate tissue which comprises contacting the prostate tissue with an effective contraction-inhibiting amount of such compound.